The risk of angiosarcoma following primary breast cancer by Cozen, W et al.
Angiosarcoma is a generic term that includes malignant sarcomas
originating from either lymphatic or capillary endothelium,
namely lymphangiosarcoma and haemangiosarcoma respectively.
Reports of lymphangiosarcoma in association with lymphoedema
of an extremity can be found as early as 1906 (Lowenstein, 1906).
The occurrence of lymphangiosarcoma in a setting of post-mastec-
tomy upper extremity oedema was originally described in a report
of six cases in 1948 (Stewart and Treves, 1948), and has since
been designated the Stewart–Treves syndrome. By 1970, 162
cases of this syndrome had been reported worldwide in case
reports and hospital case series (Sanchez et al, 1989).
Haemangiosarcoma of the chest or breast has been described in
at least two different clinical settings: in very young women with
no prior cancer (McClanahan and Hogg, 1954; Steingaszner et al,
1965) and in older women following irradiation of the breast for
epithelial breast cancer (Kuten et al, 1985; Rubin et al, 1990; Mark
et al, 1994).
Lymphangiosarcoma and haemangiosarcoma are often described
together in older reports because of the high degree of misclassifica-
tion (Woodward et al, 1972; Maddox and Evans, 1981; d’Amore et
al, 1990; Karpeh et al, 1991). In spite of recently developed
immunohistochemical antibodies, the distinction remains difficult
and even arbitrary, and the two tumours are often categorized
together as angiosarcoma. In fact, immunohistochemical and
electron microscopic studies offer equal evidence for haeman-
giomatous origin of lymphangiosarcoma (Enzinger and Weiss,
1995). The average annual age-adjusted incidence rate of angiosar-
coma for white females in the USA is 1.6/100 000 and tumours
of the upper extremity and breast account for 25% and 44%
respectively, of these sarcomas (Mack, 1995).
No formal attempt has been made previously to quantify the
relationship between invasive breast cancer and subsequent risk of
angiosarcoma, possibly because of the rarity of the tumours. We
conducted a case-control study within a population-based cancer
registry to evaluate this relationship.
MATERIALS AND METHODS
The University of Southern California Cancer Surveillance
Program (USC-CSP), the population-based cancer registry for Los
Angeles County (LAC), has been actively collecting information
on newly diagnosed invasive cancer cases since 1972 (Mack,
1977). For a given patient, each new primary cancer diagnosis is
reported separately; recurrences are not considered new diagnoses
and are not reported. The majority of diagnoses are based on
pathology reports (over 96%), with the remainder based on death
certificates or clinical diagnoses. Pathological diagnoses are not
validated by a second histological review; with over 1 million
cases of cancers diagnosed in Los Angeles since 1972, the task
would be unrealistic.
The USC-CSP registry emphasizes collection of descriptive
incidence data based on variables such as race, age, gender, birth-
place, religion, ethnicity and social class. Collection of survival
data began in 1992, when the registry became a Surveillance,
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cohort approach to assess the risk of angiosarcoma and other
sarcoma following breast cancer is not feasible and a retrospective
case-control study design was used instead.
Subjects were women who were 25 years of age or older when
diagnosed with cancer in LAC during the period 1972–1995, and
who were residents of LAC at the time of diagnosis. The study was
designed to evaluate the risk of angiosarcoma associated with a
history of invasive breast cancer; however, we also studied other
subtypes of sarcomas for comparison. Four case groups were
defined and compared to a control group consisting of non-sarcoma
female cancer patients. The first case group consisted of 20 females
diagnosed with angiosarcoma (lymphangiosarcoma and haemangio-
sarcoma; ICD-O 9120 and 9170) (Percy et al, 1991) of the upper
extremity. The second consisted of 48 females diagnosed with
lymphangiosarcoma or haemangiosarcoma of the chest and breast.
In these two groups, other types of angiosarcoma, such as Kaposi’s
sarcoma, malignant haemangioendothelioma and malignant
haemangiopericytoma, were excluded. The third and fourth case
groups consisted of female patients with other soft tissue sarcomas,
(excluding osteosarcomas; ICD-O 8800–8920) (Percy et al, 1991)
located on the upper extremity (n = 243) or the chest or breast
(n = 323) respectively. The control group (n = 266 444), consisted of
all female patients diagnosed at 25 years of age or older during the
same time period with a primary malignancy other than sarcoma.
We excluded patients with ovarian cancer, endometrial cancer and
second primary breast cancer from the control group because of the
known association of these cancers with a first primary breast cancer
(Ederer et al, 1963; Harvey and Brinton, 1985). The case and control
groups were then compared with respect to having had a prior
primary invasive breast cancer diagnosed and reported to the
registry. Since the registry collected details of the extent of disease
and type of treatment only on patients diagnosed after 1987, such
details could not be used in analysis.
Maximum likelihood estimates of the odds ratio (OR) were
calculated using multivariate unconditional logistic regression
methods; 95% confidence intervals (CI) were estimated using the
standard error of the logarithm of the OR (Breslow and Day,
1980). Race (white vs non-white), age at diagnosis (25–39, 40–54,
55–64 and 65+) and year of diagnosis (1972–1979, 1980–1987
and 1988–1995) were included in the logistic regression models.
RESULTS
The distribution of cases by histological type is shown in Table 1.
Lymphangiosarcoma is the commonest type of angiosarcoma in
the upper extremity (70%), while haemangiosarcoma makes up the
majority of chest/breast angiosarcomas (98%). Among the other
soft tissue sarcomas at these sites, fibrosarcoma, includ-
ing malignant fibrous histiocytoma, is the most frequently
diagnosed (72% in the upper extremity and 84% in the chest
and breast).
We found that women diagnosed with breast cancer have a
greatly increased risk of subsequent upper arm angiosarcoma,
compared to women who have never been diagnosed with breast
cancer (Table 2). After adjustment for age and year of sarcoma
diagnosis, and race, the observed relative risk exceeds 59 (adjusted
OR = 59.3, 95% CI = 21.9–152.8). The risk of subsequent
angiosarcoma of the chest or breast itself is also strongly and
significantly increased among women with a history of invasive
breast cancer (adjusted OR = 11.6, 95% CI = 4.3–26.1), as is the
risk of other non-vascular soft tissue sarcomas of the chest and
breast (adjusted OR = 3.29, 95% CI = 1.7–5.8). However, non-
vascular sarcoma of the upper extremity was not found to be asso-
ciated with a previous breast cancer diagnosis.
Of the eight upper extremity angiosarcoma patients with a docu-
mented previous breast cancer, five tumours occurred on the same
side as the breast cancer, one was reported to occur in the opposite
upper extremity (see below), and the laterality of the original
breast cancer was unknown for two patients. Among the six chest
or breast angiosarcoma patients with a prior history of breast
cancer, the laterality of the sequential tumours was the same in
two, and unknown in the remaining four patients. The mean
interval between the original breast cancer diagnosis and the
subsequent angiosarcoma was 9.7 years for patients with upper
extremity tumours and 4.4 years for those with chest or breast
tumours respectively.
The prior breast cancers in patients with upper extremity
angiosarcoma were diagnosed in an earlier time period compared
to prior breast cancers in control patients (mean years of diagnosis
1976 vs 1981 respectively), even though the mean age at breast
cancer diagnosis was similar in the two groups.
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Table 1 The distribution of female patients with angiosarcomas and other sarcomas, by histology, anatomic site and frequency of prior breast cancer
diagnoses. Patients were diagnosed in Los Angeles County between 1972 and 1995; those diagnosed with sarcoma under 25 years of age were excluded
Upper extremity Chest or breast Other sites
Histological subtype History of History of History of
No. (% total) breast cancer No. (% total) breast cancer No. (% total) breast cancer
Angiosarcoma (ICD-O code)
Hemangiosarcoma 9120 6 (30%) 4 47 (98%) 6 62 (94%) 0
Lymphangiosarcoma 9170 14 (70%) 4 1 (2%) 0 4 (6%) 0
Total 20 (100%) 8 48 (100%) 6 66 (100%) 0
Soft tissue sarcoma
Fibrosarcoma 8800–8841 174 (72%) 1 270 (84%) 9 974 (35%) 2
Liposarcoma 8850–8881 43 (18%) 0 26 (8%) 0 393 (15%) 0
Leiomyosarcoma 8890–8900 26 (10%) 2 27 (8%) 2 1405 (50%) 0
Total 243 (100%) 3 323 (100%) 11 2772 (100%) 2534 W Cozen et al
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DISCUSSION
Upper extremity angiosarcoma has long been reported to follow
surgery for breast cancer (Stewart and Treves, 1948; Woodward
et al, 1972; Maddox and Evans, 1981; Sanchez et al, 1989;
d’Amore et al, 1990; Karpeh et al, 1991). The proportion of upper
extremity angiosarcoma cases having had a prior breast cancer has
ranged from 32% (Maddox and Evans, 1981) to 91% (Woodward
et al, 1972). Follow-up studies (Ederer et al, 1963; Schottenfeld
and Berg, 1971; Ewertz and Mouridsen, 1985; Harvey and
Brinton, 1985; Taghian et al, 1991) of breast cancer patients have
reported increased relative risks of any subsequent soft tissue
sarcomas (including angiosarcoma) ranging from 1.8 (Taghian
et al, 1991) to 4.5 (Schottenfeld and Berg, 1971), but there have
been no attempts to quantify risk specifically for angiosarcoma,
presumably because there were too few cases. We estimate this
relative risk to be at least 59. The mean interval between breast
cancer diagnosis and subsequent upper extremity angiosarcoma in
our study was 9.7 years, similar in magnitude to that reported in
other cases series (Woodward et al, 1972; Maddox and Evans,
1981; Janse et al, 1995).
In this case-control study, patients with cancer known to be
associated with an increased risk of breast cancer were excluded
from the control group in order to avoid biasing the result towards
the null. While this may have caused the risk estimate to be
slightly overestimated, we actually believe the relative risk of 59 to
be a net underestimate due to the unavoidable under-ascertainment
of breast cancers diagnosed prior to 1972. Upon review of the
pathology reports of the 20 upper extremity angiosarcoma
patients, we found evidence of breast cancer diagnosed prior to the
existence of the registry for four of the 12 classified as ‘unex-
posed’. One out of a sample of 34 ‘unexposed’ non-sarcoma
control cancer patients had evidence of a prior breast cancer, and
none of the 42 ‘unexposed’ patients with chest or breast angiosar-
coma had such evidence. Thus, it is likely that the magnitude of
the risk for upper extremity angiosarcoma is considerably higher
than the observed 59-fold increase.
Post-mastectomy lymphoedema due to lymphatic blockage
and/or radiation have been postulated as risk factors for the
development of soft-tissue sarcomas following breast cancer
(McClanahan and Hogg, 1954; Woodward et al, 1972; Maddox
and Evans, 1981; Appelqvist et al, 1990; d’Amore et al, 1990;
Karpeh et al, 1991). The majority of upper extremity lymph-
angiosarcoma cases had developed lymphoedema of the ipsilateral
upper extremity following surgery for breast cancer and most, but
not all, had received radiation therapy as part of their breast cancer
treatment (Stewart and Treves, 1948; McClanahan and Hogg,
1954; Woodward et al, 1972; Maddox and Evans, 1981; Sanchez
et al, 1989; Appelqvist et al, 1990; d’Amore et al, 1990; Rubin
et al, 1990; Karpeh et al, 1991). The pathogenic mechanism by
which lymphangiosarcoma develops is not known. However,
lymphangiomatosis (proliferation of lymphatic vessels) is often
seen in uninvolved areas of the affected oedematous extremity
(Woodward et al, 1972), suggesting that lymphatic blockage stim-
ulates the growth of lymphatic vessels, possibly via cytokines such
as vascular endothelial growth factor (VEGF).
While one of these reported breast cancers (among the upper
extremity angiosarcoma patients) had occurred contralateral to
the subsequent angiosarcoma, this does not constitute evidence
against a local mechanism. It is possible that this patient had
bilateral breast cancer, with an initial primary occurring on the
ipsilateral side prior to 1972 and therefore unidentified.
It is unclear if radiation contributes to the increase in risk. It
could do so indirectly by causing axillary node sclerosis thereby
producing lymphatic blockage and lymphoedema, or alternatively,
by direct DNA damage. However, in the years of high-dose radia-
tion, the upper extremity was protected from radiation by a lead
shield. Since then, the trend has been to narrow and focus the beam
of radiation on the tumour and axillary nodes, thereby reducing
even further the likelihood of direct exposure of the upper
extremity to ionizing radiation. A direct relationship between radi-
ation therapy and subsequent sarcoma of the chest wall itself is
more likely and has been suggested previously (Senyszyn et al,
1970; Kim et al, 1978; Ferguson et al, 1984; Souba et al, 1986;
Taghian et al, 1991; Wiklund et al, 1991), although the majority of
reported post-radiation sarcomas have been malignant fibrous
histiocytoma, osteosarcoma and fibrosarcoma, rather than
angiosarcoma. We could not address this question directly in the
absence of detailed treatment data. However, the significant
increase in both vascular and non-vascular chest wall sarcomas
following a diagnosis of breast cancer certainly supports radiation
exposure as a cause of sarcoma, although the magnitude of the risk
Table 2 Odds ratios (OR) and 95% confidence intervals (CI) for the risk of having a prior breast cancer among Los Angeles County female residents over 25
years of age diagnosed with angiosarcomasa and other sarcomasb of the upper extremity or chest between 1972 and 1995, compared to those with all other
malignancies (controls)c
Exposure
History of No history of Unadjusted Adjusted 95% CI
breast cancer prior breast OR OR
1972–1995 cancer
Angiosarcomaa
Upper extremity 8 12 47.6 59.3 21.9–152.8
Chest/breast 6 42 10.2 11.6 4.3–26.1
Other soft tissue sarcomab
Upper extremity 3 240 0.9 1.1 0.3–2.8
Chest/breast 11 312 2.5 3.3 1.1–1.7
All other malignanciesc 3634 262 810
aAngiosarcoma (haemangiosarcoma and lymphangiosarcoma only). bFibrosarcoma (including myxosarcoma and malignant fibrous histiocytoma),
leiomyosarcoma, liposarcoma. cExcluding endometrial, ovarian and breast cancer, and all sarcoma except osteosarcoma. dAdjusted for age, race and year of
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was higher for angiosarcomas (OR = 11.6) than for other sarcomas
(OR = 3.3).
Although the relative odds for lymphangiosarcoma of the upper
extremity following breast cancer is high, the absolute risk is low;
the age-adjusted annual incidence in Los Angeles County females
is only 0.02 per 100 000 women (USC-CSP, unpublished data). If
lymphatic blockage and the resultant local lymphoedema were
sufficient causes of upper extremity angiosarcoma, one would
expect to have seen many more cases. An average of 6000 new
breast cancers have been diagnosed annually in Los Angeles
County between 1972 and 1995, and an estimated 13–37% of
these patients are estimated to have developed long-term
lymphoedema (Larson et al, 1986). Thus it is likely that additional
factors are required. An inherited mutation in a tumour suppressor
gene such as p53 (Malkin et al, 1990) might provide a permissive
circumstance in which lymphatic blockage and the resultant
lymphangiomatosis could lead to angiosarcoma. In fact, one
patient with bilateral breast cancer and an upper extremity
angiosarcoma has been tested in another context and found to have
the BRCA1 mutation, 185delAG. Recent reports provide evidence
that murine BRCA1 may have enzymatic activity involved with
DNA repair (Somasundaram et al, 1997).
The eight upper extremity angiosarcoma patients who had a
previous diagnosis of breast cancer reported to the registry had all
been diagnosed with their breast cancer before 1981 (Table 3), and
the four identified by pathology reports and not reported to the
registry are presumed to have occurred before 1972. These breast
cancers occurred during a period when the Halstead radical
mastectomy with extensive axillary dissection was still in vogue.
In contrast, the six patients who developed a subsequent angio-
sarcoma of the chest wall were diagnosed with breast cancer later,
mostly in the late 1980s and early 1990s, during a period in which
breast-conserving surgery with supplemental radiation therapy
was more popular. These observations suggest that while the
incidence of upper extremity angiosarcoma subsequent to breast
cancer is probably decreasing, that of secondary angiosarcoma of
the chest wall may be increasing. If the risk of developing
angiosarcoma after radiation is associated with a constitutional
characteristic, such as an inherited mutation, some of these highly
fatal secondary cancers might be prevented by altering therapeutic
strategies for those who are susceptible.
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